Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment
Identifieur interne : 001028 ( Main/Exploration ); précédent : 001027; suivant : 001029Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment
Auteurs : Bhomraj Thanvi [Royaume-Uni] ; Nelson Lo ; Tom RobinsonSource :
- Postgraduate Medical Journal [ 0032-5473 ] ; 2007-06.
English descriptors
- KwdEn :
- 5-HT, 5-hydroxytryptamine, COMT, catechol-O-methyl transferase, D-I-D, dyskinesia-improvement-dyskinesia, FRA, Fos-related proteins, GABA, γ-aminobutyric acid, GPDRS, Global Primate Dyskinesia Rating Scale, GPi, internal globus pallidum, LID, levodopa-induced dyskinesias, MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NMDA, N-methyl-D-aspartate, RAM, rapid alternating movements, STN, subthalamic nucleus, UPDRS, Unified Parkinson’s Disease Rating Scale.
Abstract
Levodopa is the most effective drug for treating Parkinson’s disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson’s disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa-induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non-human primates with MPTP-induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson’s disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare.
Url:
DOI: 10.1136/pgmj.2006.054759
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment</title><author><name sortKey="Thanvi, Bhomraj" sort="Thanvi, Bhomraj" uniqKey="Thanvi B" first="Bhomraj" last="Thanvi">Bhomraj Thanvi</name></author><author><name sortKey="Lo, Nelson" sort="Lo, Nelson" uniqKey="Lo N" first="Nelson" last="Lo">Nelson Lo</name></author><author><name sortKey="Robinson, Tom" sort="Robinson, Tom" uniqKey="Robinson T" first="Tom" last="Robinson">Tom Robinson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D15236066AEAFF36F68FA39468D8030A84D5CAC</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1136/pgmj.2006.054759</idno><idno type="url">https://api.istex.fr/document/2D15236066AEAFF36F68FA39468D8030A84D5CAC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000F23</idno><idno type="wicri:Area/Main/Curation">000D48</idno><idno type="wicri:Area/Main/Exploration">001028</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment</title><author><name sortKey="Thanvi, Bhomraj" sort="Thanvi, Bhomraj" uniqKey="Thanvi B" first="Bhomraj" last="Thanvi">Bhomraj Thanvi</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Integrated Medicine, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester</wicri:regionArea><wicri:noRegion>Leicester</wicri:noRegion></affiliation></author><author><name sortKey="Lo, Nelson" sort="Lo, Nelson" uniqKey="Lo N" first="Nelson" last="Lo">Nelson Lo</name><affiliation><wicri:noCountry code="no comma">Leicester General Hospital</wicri:noCountry></affiliation></author><author><name sortKey="Robinson, Tom" sort="Robinson, Tom" uniqKey="Robinson T" first="Tom" last="Robinson">Tom Robinson</name><affiliation><wicri:noCountry code="subField">Leicester General Hospital</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Postgraduate Medical Journal</title><title level="j" type="abbrev">Postgrad Med J</title><idno type="ISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><imprint><publisher>The Fellowship of Postgraduate Medicine</publisher><date type="published" when="2007-06">2007-06</date><biblScope unit="volume">83</biblScope><biblScope unit="issue">980</biblScope><biblScope unit="page" from="384">384</biblScope></imprint><idno type="ISSN">0032-5473</idno></series><idno type="istex">2D15236066AEAFF36F68FA39468D8030A84D5CAC</idno><idno type="DOI">10.1136/pgmj.2006.054759</idno><idno type="href">postgradmedj-83-384.pdf</idno><idno type="PMID">17551069</idno><idno type="local">0830384</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0032-5473</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT, 5-hydroxytryptamine</term><term>COMT, catechol-O-methyl transferase</term><term>D-I-D, dyskinesia-improvement-dyskinesia</term><term>FRA, Fos-related proteins</term><term>GABA, γ-aminobutyric acid</term><term>GPDRS, Global Primate Dyskinesia Rating Scale</term><term>GPi, internal globus pallidum</term><term>LID, levodopa-induced dyskinesias</term><term>MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>NMDA, N-methyl-D-aspartate</term><term>RAM, rapid alternating movements</term><term>STN, subthalamic nucleus</term><term>UPDRS, Unified Parkinson’s Disease Rating Scale</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the most effective drug for treating Parkinson’s disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson’s disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa-induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non-human primates with MPTP-induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson’s disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Lo, Nelson" sort="Lo, Nelson" uniqKey="Lo N" first="Nelson" last="Lo">Nelson Lo</name><name sortKey="Robinson, Tom" sort="Robinson, Tom" uniqKey="Robinson T" first="Tom" last="Robinson">Tom Robinson</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Thanvi, Bhomraj" sort="Thanvi, Bhomraj" uniqKey="Thanvi B" first="Bhomraj" last="Thanvi">Bhomraj Thanvi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001028 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001028 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2D15236066AEAFF36F68FA39468D8030A84D5CAC
|texte= Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment
}}
| This area was generated with Dilib version V0.6.23. |  |